异环磷酰胺与阿瑞匹坦在妇科恶性肿瘤中的相互作用。
The interaction of ifosfamide and aprepitant in gynecologic malignancies.
作者信息
Shindorf Mackenzie L, Manahan Kelly J, Geisler John P
机构信息
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Toledo, College of Medicine & Life Sciences, Toledo, OH, USA.
出版信息
Gynecol Oncol Case Rep. 2013 Jun 12;6:34-5. doi: 10.1016/j.gynor.2013.06.002. eCollection 2013.
Abstract
•Aprepitant combined with ifosfamide may lead to encephalopathy.•Aprepitant-ifosfamide induced encephalopathy was of short duration in these cases.
摘要
•阿瑞匹坦与异环磷酰胺联用可能导致脑病。•在这些病例中，阿瑞匹坦-异环磷酰胺所致脑病持续时间较短。
相似文献
1
The interaction of ifosfamide and aprepitant in gynecologic malignancies.异环磷酰胺与阿瑞匹坦在妇科恶性肿瘤中的相互作用。
Gynecol Oncol Case Rep. 2013 Jun 12;6:34-5. doi: 10.1016/j.gynor.2013.06.002. eCollection 2013.
2
Two cases of fatal encephalopathy related to Ifosfamide: an adverse role of aprepitant?两例与异环磷酰胺相关的致命性脑病：阿瑞匹坦的不良作用？
Case Rep Oncol. 2014 Sep 25;7(3):669-72. doi: 10.1159/000368184. eCollection 2014 Sep.
3
Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide.群体药代动力学分析显示，阿瑞匹坦对异环磷酰胺、2-去氯异环磷酰胺和3-去氯异环磷酰胺的药代动力学没有影响。
Eur J Pharm Sci. 2023 Jun 1;185:106420. doi: 10.1016/j.ejps.2023.106420. Epub 2023 Mar 5.
4
Ifosfamide-induced Encephalopathy Precipitated by Aprepitant: A Rarely Manifested Side Effect of Drug Interaction.阿瑞匹坦诱发的异环磷酰胺脑病：一种罕见的药物相互作用副作用表现
J Pharmacol Pharmacother. 2017 Jan-Mar;8(1):38-40. doi: 10.4103/jpp.JPP_182_16.
5
Possible contribution of aprepitant to ifosfamide-induced neurotoxicity.阿瑞匹坦对异环磷酰胺所致神经毒性的潜在影响。
Am J Health Syst Pharm. 2008 Dec 1;65(23):2229-31. doi: 10.2146/ajhp080069.
6
[Errata: A Case of Encephalopathy Caused by Drug Interaction between Ifosfamide and Aprepitant].
Yakugaku Zasshi. 2023;143(7):621. doi: 10.1248/yakushi.143.621.
7
Characterization of the occurrence of ifosfamide-induced neurotoxicity with concomitant aprepitant.异环磷酰胺诱导的神经毒性与阿瑞匹坦联用的发生特征
J Oncol Pharm Pract. 2008 Sep;14(3):157-62. doi: 10.1177/1078155208093930.
8
Phase II experience with ifosfamide/mesna in gynecologic malignancies: preliminary report of Gynecologic Oncology Group studies.异环磷酰胺/美司钠治疗妇科恶性肿瘤的II期经验：妇科肿瘤学组研究的初步报告
Semin Oncol. 1989 Feb;16(1 Suppl 3):68-72.
9
Efficacy, Tolerability and Pharmacokinetic Impact of Aprepitant in Sarcoma Patients Receiving Ifosfamide and Doxorubicin Chemotherapy: A Randomized Controlled Trial.阿瑞匹坦在骨肉瘤患者接受异环磷酰胺和多柔比星化疗中的疗效、耐受性和药代动力学影响：一项随机对照试验。
Adv Ther. 2019 Feb;36(2):355-364. doi: 10.1007/s12325-018-0862-2. Epub 2019 Jan 3.
10
Antiemetic neurokinin-1 antagonist aprepitant and ifosfamide-induced encephalopathy.止吐神经激肽-1拮抗剂阿瑞匹坦与异环磷酰胺诱导的脑病
Ann Oncol. 2007 Apr;18(4):808-9. doi: 10.1093/annonc/mdm104.
引用本文的文献
1
A narrative review on diagnosis and treatment of ifosfamide-induced encephalopathy, the perspective of a EURACAN reference center for sarcomas.一篇关于异环磷酰胺所致脑病诊断与治疗的叙述性综述：欧洲肉瘤参考中心视角
Front Pharmacol. 2025 Feb 21;16:1512966. doi: 10.3389/fphar.2025.1512966. eCollection 2025.
2
Influence of aprepitant on the pharmacodynamics and pharmacokinetics of gliclazide in rats and rabbits.阿瑞匹坦对大鼠和兔体内格列齐特药效学和药代动力学的影响。
PeerJ. 2018 May 22;6:e4798. doi: 10.7717/peerj.4798. eCollection 2018.
3
Aprepitant and fosaprepitant drug interactions: a systematic review.阿瑞匹坦和福沙匹坦的药物相互作用：系统评价。
Br J Clin Pharmacol. 2017 Oct;83(10):2148-2162. doi: 10.1111/bcp.13322. Epub 2017 Jun 10.
本文引用的文献
1
Current management of ovarian carcinosarcoma.卵巢癌肉瘤的当前管理
Int J Gynecol Cancer. 2007 Mar-Apr;17(2):316-24. doi: 10.1111/j.1525-1438.2006.00760.x.
2
Ifosfamide encephalopathy.异环磷酰胺脑病
Clin Oncol (R Coll Radiol). 2007 Mar;19(2):108-14. doi: 10.1016/j.clon.2006.11.003.
3
Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.异环磷酰胺联合或不联合紫杉醇治疗晚期子宫癌肉瘤的III期试验：一项妇科肿瘤学组研究
J Clin Oncol. 2007 Feb 10;25(5):526-31. doi: 10.1200/JCO.2006.06.4907.
4
Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients.阿瑞匹坦添加到由昂丹司琼和地塞米松组成的标准止吐方案中时，不会影响癌症患者中长春瑞滨的药代动力学。
Cancer Chemother Pharmacol. 2007 Feb;59(3):407-12. doi: 10.1007/s00280-006-0359-6. Epub 2006 Oct 19.
5
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.美国临床肿瘤学会肿瘤学止吐指南：2006年更新版
J Clin Oncol. 2006 Jun 20;24(18):2932-47. doi: 10.1200/JCO.2006.06.9591. Epub 2006 May 22.
6
Carcinosarcoma of the ovary-a case series.卵巢癌肉瘤——病例系列
Gynecol Oncol. 2006 Jan;100(1):128-32. doi: 10.1016/j.ygyno.2005.07.119. Epub 2005 Oct 5.
7
On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus.关于辅助盆腔放疗未能提高局限于子宫的子宫肉瘤女性患者生存率的情况。
Am J Clin Oncol. 2005 Jun;28(3):295-300. doi: 10.1097/01.coc.0000156919.04133.98.
8
Systemic therapy for advanced uterine sarcoma: a systematic review of the literature.晚期子宫肉瘤的全身治疗：文献系统评价
Gynecol Oncol. 2005 May;97(2):624-37. doi: 10.1016/j.ygyno.2005.01.041.
9
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.剂量和输注持续时间对异环磷酰胺及其代谢产物药代动力学的影响。
Drug Metab Dispos. 2001 Jul;29(7):967-75.
Zotero 插件